Sector Gamma AS Boosts Position in Pfizer Inc. (NYSE:PFE)

Sector Gamma AS boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 40.9% during the fourth quarter, HoldingsChannel reports. The fund owned 1,155,000 shares of the biopharmaceutical company’s stock after purchasing an additional 335,000 shares during the quarter. Pfizer comprises 10.5% of Sector Gamma AS’s holdings, making the stock its largest position. Sector Gamma AS’s holdings in Pfizer were worth $30,642,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Lakeshore Financial Planning Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at $327,000. Wayfinding Financial LLC bought a new position in Pfizer during the fourth quarter worth $214,000. Goodman Financial Corp boosted its stake in Pfizer by 5.5% during the fourth quarter. Goodman Financial Corp now owns 432,271 shares of the biopharmaceutical company’s stock worth $11,468,000 after acquiring an additional 22,609 shares in the last quarter. DCF Advisers LLC boosted its stake in Pfizer by 49.5% during the fourth quarter. DCF Advisers LLC now owns 51,350 shares of the biopharmaceutical company’s stock worth $1,362,000 after acquiring an additional 17,000 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC boosted its stake in Pfizer by 78.2% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 85,776 shares of the biopharmaceutical company’s stock worth $2,276,000 after acquiring an additional 37,653 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PFE shares. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

PFE opened at $26.17 on Friday. The company has a market capitalization of $148.29 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average price of $26.18 and a 200-day moving average price of $27.07. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.